Association between fibrinogen‐to‐albumin ratio and prognosis of patients with heart failure

Abstract Background Systemic inflammation is closely associated with the development and progression of heart failure (HF), increasing vulnerability to thromboembolic events. This retrospective cohort study assessed the potential of the fibrinogen‐to‐albumin ratio (FAR), a new inflammatory biomarker, as a prognostic indicator for HF risk. Methods One thousand one hundred and sixty six women and 826 men with a mean age of 70.70 ± 13.98 years were extracted from the Medical Information Mart for Intensive Care‐IV (MIMIC‐IV v2.0) database. Additionally, a second cohort was obtained, including 309 patients from the Second Affiliated Hospital of Wenzhou Medical University. The relationship between FAR and the prognosis of HF was evaluated using multivariate analysis, propensity score‐matched analysis, and subgroup analysis. Results Fibrinogen‐to‐albumin ratio was an independent risk factor for 90‐day all‐cause mortality (hazard ratio: 1.19; 95% confidence interval (CI): 1.01–1.40), 1‐year all‐cause mortality (hazard ratio: 1.23; 95% confidence interval: 1.06–1.41), and length of hospital stay (LOS) (β: 1.52; 95% CI: 0.67–2.37) in the MIMIC‐IV dataset, even after adjusting for potential covariates. These findings were verified in the second cohort (β: 1.82; 95% CI: 0.33–3.31) and persisted after propensity score‐matching and subgroup analysis. FAR was positively correlated with C‐reactive protein, NT‐proBNP, and Padua score. The correlation between FAR and NT‐proBNP ( R = .3026) was higher than with fibrinogen ( R = .2576), albumin ( R = −.1822), platelet‐to‐albumin ratio ( R = .1170), and platelet‐to‐lymphocyte ratio ( R = .1878) ( p s < .05). Conclusions Fibrinogen‐to‐albumin ratio is an independent risk prognostic factor for 90‐day, 1‐year all‐cause mortality and LOS among HF patients. Inflammation and prothrombotic state may underlie the relationship between FAR and poor prognosis in HF.